Following treatment, a decreased proportion of epithelial and fibroblast cells was observed, whereas NK cells, T cells, and myeloid cells showed increased proportions, correcting an earlier misstatement.
"As we look to the future, I am excited to lead us into the next chapter - expanding our reach, deepening our academic mission, and advancing care for the patients and communities we serve."
Yaw Bediako, an immunologist, founded Yemaachi Biotech to address the significant lack of cancer research in Africa, highlighting the continent's hidden cancer burden.
"It's a super exciting clinical tool that we now have available... We are already getting calls and emails from colleagues and from dog owners from all over the world."
